These factors compromise Canadian women's access to abortion care.
Medication abortion (the use of a drug or combination of drugs to terminate a pregnancy) could improve abortion care across Canada. Although acceptable protocols vary, in combination regimens, 2 drugs are administered to effect the abortion over time. The first drug is administered in a health facility to interfere with the continuation of pregnancy. The second drug is taken by the woman at home after a set number of days to facilitate expulsion of the products of conception. A follow-up visit is then required to confirm a complete abortion. 6 By contrast to surgical abortion (insertion of an instrument to remove the products of conception from the uterus), medication abortion requires less technical skill and simpler health care infrastructure. It may therefore be delivered in a broader range of health care facilities and offered by a more diverse and larger set of providers. 7 Medication abortion is also experienced differently than surgical abortion. Women find medication abortion to be more private, because it happens at home over time, akin to a natural miscarriage. Many women prefer this experience and elect medication over surgical abortion. 8 Medication abortion could improve abortion care in Canada, but its potential remains unrealized. Only 1% to 2% of Canadian abortions are pharmaceutically induced. 9 This underutilization can be attributed in part to the unavailability of an acceptable method of medication abortion. Canada is one of few developed countries that have not approved mifepristone, the safest and most effective pharmaceutical for medication abortion. Given that mifepristone could improve abortion care in Canada by rendering medication abortion a real rather than potential alternative to surgical care, we investigated whether the unavailability of mifepristone in Canada is attributable to government inaction and thus whether Canada is failing to fulfill its obligations under the international right to health.
ABORTION CARE AND THE INTERNATIONAL HUMAN RIGHT TO HEALTH
As a state party to the ICESCR, Canada recognizes ''the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.'' 1 The right to health consists of an entitlement to the enjoyment of goods and services necessary for the realization of the highest attainable standard of health. 10 This entitlement is reflected in Canadian health care policy, which seeks to protect, promote, and restore the physical and mental well-being of Canadian residents by facilitating their reasonable access to medically necessary health care without financial or other barriers.
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Canada has further undertaken to implement the right to health without discrimination, including discrimination against women. A major burden of women's ill health is related to reproduction, and reproductive health care is therefore identified as a priority obligation under the right to health. 10 Realization of the highest attainable standard of health requires that women have the freedom to decide whether and when to reproduce and the right to health care necessary to effectuate their decisions.
Goods and services relating to pregnancy termination are important components of reproductive health care. The UN expert body that supervises state parties' implementation of the right to health under the ICESCR has consistently advised state parties to review criminal laws on abortion because of their adverse consequences for women's health. [12] [13] [14] Abortion is a safe and effective intervention that serves important physical and mental health needs. Abortion terminates the unwanted physical state of pregnancy and avoids the physical and mental health risks of gestation, delivery, and postpartum recovery. Abortion also serves important nonmedical ends, contributing to a woman's broader social well-being.
Canadian law and policy recognize abortion as a component of reproductive health care. In 1995, the federal minister of health enacted a policy interpreting clinic abortion services as medically necessary, 15 thereby requiring provinces to fund these services. In 2006, a Quebec court ordered the government to reimburse 45 000 women for out-of-pocket clinic expenses incurred for abortion services. 16 In upholding the constitutionality of legislation regulating abortion clinic protest activity, a British Columbia court stated, ''A woman's right to access health care without unnecessary loss of privacy and dignity is no more than the right of every Canadian to access health care.'' 17 The right to health under the ICESCR requires that reproductive health care, including abortion-related goods and services, is available, accessible, and acceptable. 10 Goods and services should be available in sufficient quantity; geographically and economically accessible to all women, in particular vulnerable and marginalized women; and delivered in a respectful manner. These interrelated features of the right to health-availability, accessibility, and acceptability-are the standard against which to assess abortion care in Canada.
ABORTION CARE IN CANADA
Since judicial decriminalization of abortion in 1988, 18 induced abortion rates in Canada have exhibited a general decline. 4 This trend may reflect a decline in unwanted pregnancies and thus in the need for abortion. It may also indicate a decline in the availability, accessibility, and acceptability of abortion care and thus a decline in health care necessary for the realization of women's highest attainable standard of health. Two related factors support the latter interpretation. First, the availability and accessibility of surgical abortion facilities and providers are decreasing. Second, an acceptable method of medication abortion, an alternative to early term (within the first 9 weeks of gestation) surgical abortion, remains unavailable in Canada.
Surgical Abortion Facilities and Providers
The vast majority of early term abortions are surgically performed in hospital and clinic facilities. Although abortion is one of the most frequently performed of all surgical procedures, 19 Unreasonable wait times led to a constitutional challenge in Manitoba. 21 Timely access to health care is an essential feature of the right to health. 10 Excessive delay in hospital abortion care is often related to the unavailability of operating rooms and providers. 22 Many hospitals, for example, lack willing and trained providers. Only half of all Canadian medical schools teach surgical abortion techniques, dedicating less than 1 hour of instruction to the subject in a 4-year curriculum. 23 Surgical abortion training during obstetrics and gynecology residency is neither extensive nor mandatory, with only 20% of those trained providing abortions after residency. 23 With an aging population of willing and trained providers, the availability of surgical abortion in Canada will likely continue to decline. Lacking access to timely hospital services, women increasingly seek or are referred to abortion care in clinics. Between 1993 and 2004, the percentage of clinic abortions in Canada doubled from 23% to 46%. 4 Clinics are perceived to offer care that is more comprehensive and supportive and of better quality than that received in hospitals. Clinic facilities, however, exist in only 8 of the 10 provinces and only in urban centers. 5 The result of geographical disparity in the availability of hospital and clinic facilities is that many Canadian women must travel within or between provinces to obtain care. Travel often entails economic and personal costs. Women must schedule time off work, arrange for child care services, and pay out of pocket for travel, accommodation, and in many provinces, the service itself. 5 Although some women value the increased privacy that may attend receiving abortion care outside their community, others are denied needed support from partners, family, and friends. Moreover, the associated costs of travel disproportionately affect vulnerable and marginalized women, contrary to the right to health standard. 10 
Medication Abortion
A decrease in the availability and accessibility of surgical abortion care is not necessarily an infringement of the right to health. This trend may indicate a fulfillment of the right to health if surgical abortion services are complemented by a more available, accessible, and acceptable method. Medication abortion represents such an alternative method.
Following pregnancy diagnosis and accurate gestational dating, women undergoing medication abortion first receive either mifepristone or methotrexate in a health facility and self-administer a different drug, misoprostol, at home after a set interval. The first drug interferes with the continuation of pregnancy. Misoprostol expels the products of conception from the uterus. Medication abortion occurs as a process over an extended period rather than as a discrete surgical event. A follow-up visit to the health facility is therefore required to confirm a complete abortion by serum hCG measurement or ultrasound or to complete the abortion by surgical evacuation if necessary. 6 Medication abortion is noninvasive, and the facilities and skills it requires are less specialized than those for surgical abortion; it can thus be delivered by a larger set of providers in a broader range of facilities. Medication abortion also allows physicians to offer abortion care more discreetly. If they feel less exposed and thus less vulnerable to hostility, violence, and other risks, more family physicians may provide abortions. 7 Family physicians who offer medication abortion in their offices could thus diminish the provider barriers that impede access to surgical abortion.
Medication abortion offers a different experience of abortion that may be more acceptable to and thus preferred by some women. Because no instruments are involved, many women describe a more natural experience, with their uterine pain resembling a miscarriage or menstrual cramps. 8 Medication abortion may also be experienced as more private and respectful of the woman's dignity and as generating a more egalitarian clinical interaction. The administration of mifepristone or methotrexate while the woman is dressed and the selfadministration of misoprostol at home engender a feeling of greater control.
Many women, however, do not prefer medication abortion. Those who prefer surgical abortion cite uterine pain, the longer duration, and discomfort or fear about aborting at home without professional supervision as their reasons. 8 Neither medication nor surgical abortion is thus the preferred method of all women seeking abortion. Research suggests, however, that when offered a choice between abortion methods, most women express a preference for one method. 8 Acceptable care
in the delivery of abortion services, including respect for a woman's choice among equally safe and cost-effective methods, is an essential feature of the right to health. 10 Medication abortion could improve abortion care in Canada, but its potential remains unrealized. The number of medication abortions performed countrywide is difficult to assess, but it is estimated that only 1% to 2% of all abortions are pharmaceutically induced. 9 One quarter of all abortions are performed within the first 9 weeks of gestation and are thus eligible for medication abortion. 4 An even higher percentage might be eligible, because many women may request an abortion within the gestational limit for medication abortion but experience delays in receiving surgical abortion care. The question is thus, Why is medication abortion in Canada underused?
The Unrealized Potential of Mifepristone
Underutilization can be attributed in part to the unavailability of an acceptable method of medication abortion. Mifepristone, the safest and most effective pharmaceutical for medication abortion, has not been approved for use in Canada. Mifepristone is the only medicine indicated for early term pregnancy termination, and its combined use with misoprostol is the only medication abortion regimen recommended by the World Health Organization. 26 As of 2007, 36 countries worldwide, including the United States and many European countries, have approved mifepristone for use in early pregnancy termination. 27 In France, Scotland, and Sweden, more than half of eligible abortions are pharmaceutically induced with mifepristone. 28 In the vast majority of medication abortions in Canada, methotrexate (in an off-label use) is substituted for mifepristone in combination regimens. 25 Methotrexate is registered in Canada for several indications, including the treatment of cancer, arthritis, and ectopic pregnancy. 29 Methotrexate is safe and effective, but because it takes longer to work, is less acceptable to women, and is not approved for use in medication abortion; it is an inferior substitute. 30 Providers must be willing to educate themselves about appropriate clinical use for pregnancy termination and to prescribe off label in a practice area (obstetrics and gynecology) with high liability risk; both of these factors are further barriers to wide availability. The ICESCR designates states' obligation to ensure the availability of essential drugs as a core obligation under the right to health. 10 Canada, like all state signatories, is required to undertake measures, whether legislative, administrative, or budgetary, to ensure women's access to essential reproductive health medicines. 10 26(p36) The list is intended to guide governments in the selection of medicines that are essential for their population and that should thus be available in their health systems. The ultimate designation of medicines as essential remains, however, a national responsibility, to be determined by the priority health needs of a country's population. 31 A prime motivation in adding mifepristone and misoprostol to the list was decreasing abortion-related mortality in developing countries. Although abortion-related maternal death is not a priority concern in Canada, service delivery barriers to surgical abortion and the unacceptability of medication abortion with methotrexate create a public health need for mifepristone.
The International Right to Health Standard
In Canada today, the availability and accessibility of surgical abortion facilities and providers are decreasing, and an acceptable method of medication abortion is not available. Canadian women are denied enjoyment of reproductive health care necessary for the realization of the highest attainable standard of health. Abortion care in Canada may thus represent a failure of government to fulfill its international legal obligations under the right to health.
The failure lies not in the state of abortion care in Canada, but in government responsibility for this state. The ICESCR holds governments accountable for the state of health care. It does not require that a government immediately meet the standard of available, accessible, and acceptable health goods and services. 10 There may be valid reasons why the standard cannot be immediately achieved. The right to health requires that government strive toward realization of this standard-undertaking legislative, administrative, and budgetary measures to ensure available, accessible, and acceptable health care-and to publicly account for its action or inaction. 10 
RESPONSIBILITY FOR MIFEPRISTONE'S UNAVAILABILITY
Approval of medicines by the Federal Department of Health (Health Canada) is based on evidence of safety and efficacy. The World Health Organization Model List of Essential Medicines is authoritative evidence that use of mifepristone and misoprostol in pregnancy termination is both safe and cost effective. As early as 2003, the Society of Obstetricians and Gynaecologists of Canada noted the development, testing, approval, and medical acceptability of mifepristone in the United States, and several European countries supported its introduction into Canada for clinical use.
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The unavailability of mifepristone in Canada cannot therefore be attributed to safety or efficacy concerns.
The unavailability of mifepristone is routinely attributed to the Canadian drug approval process, which can be initiated only by application from a pharmaceutical company. 33 Mifepristone remains unapproved in Canada because Health Canada has received no application. Two barriers are commonly cited for this absence: financial incentive and political bias.
Financial Incentive
In many countries, medication abortion has proven less profitable than expected. In Canada, it is predicted that revenues will be moderate because of cost controls and will not offset high regulatory approval costs. Revenues from abortifacient medicines are expected to be lower than from other drug products because of their relatively infrequent use and the likelihood of negotiated pricing with public agencies and professional groups. Although Health Canada has sought to address financial barriers to drug approval applications through a cost-reduction program, its eligibility criteria target orphan drugs, medicines for rare diseases. 34 No similar program addresses drugs that have public health importance but limited financial promise. Health Canada also has procedures for priority review and approval of critical new drugs and breakthrough therapies. To obtain priority status, however, the drug must be intended for lifethreatening or other serious conditions, and clinical trials must have demonstrated that it significantly increases efficacy or decreases risk compared with existing therapies. 35 Given that medication abortion is neither safer nor more effective than surgical abortion and that access to existing interventions is not considered, mifepristone is unlikely to qualify for priority status.
Political Bias
Bias against reproductive health medicines, and especially abortifacient drugs, may also act as a strong disincentive for application. Health Canada has been perceived as biased against reproductive health medicines, largely because of stringent requirements for the approval of oral contraceptives. 36 The re- Applications for mifepristone worldwide have met with legal and political opposition as well as heightened scrutiny from public agencies. When mifepristone was approved in Switzerland, for example, a legal challenge (ultimately unsuccessful) was mounted to reverse the decision of the InterCantonal Office for Control of Medicines. 39 In Luxembourg, the minister for health sought the opinion of a national advisory health and bioethics commission as part of the approval process.
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As a result of delays and costs associated with political opposition and stringent approval processes, the former patent holder of mifepristone adopted a corporate policy to submit the drug for approval only if invited to do so by a government official. 41 
Government Inaction
Although Health Canada has not refused to approve mifepristone, neither has the government fulfilled its human rights obligations to ensure that this reproductive health medicine is available and accessible in Canada.
Health Canada programs to ensure access to unapproved drugs do little to increase access to medicines intended for public health benefit. Physicians must file an application for each patient to be considered individually. 42 This process is not only cumbersome but also likely to produce inequalities in access. In Australia, where mifepristone is also unapproved, physicians may apply to a government agency for the authority to import and prescribe the drug. Mifepristone, thus, remains restricted to a handful of women, and physicians ''appear to be experiencing great difficulties obtaining approval to extend access to the drug.'' 43(p173) It can be argued that Health Canada is simply not authorized to solicit an application for approval of mifepristone from the pharmaceutical industry. Such a passive regulatory system is designed to maintain independence and transparency in drug review and approval. Although a passive system may be broadly justified on this basis, blind adherence to the system without concern for its effects is contrary to the right to health. Government may not obstruct the approval of safe and effective medicines, nor may it remain passive when financial and political barriers impede the introduction of essential reproductive health medicines into the market. Government is obligated to ensure that an applicant-driven drug approval process does not impede the availability of essential reproductive health medicines.
Health Canada's existing costreduction, priority-review, and special-access programs establish a precedent for government action to correct flaws in the system. These programs are exceptions to the rule of government independence, suggesting that neutrality is not an essential feature of the system. In fact, proposed regulatory reforms expressly seek to promote early engagement and to shift regulatory paradigms away from ''a passive system that is activated by events, rather than influencing outcomes.'' 44 The un- 
CONCLUSION
The unavailability of an acceptable method of medication abortion in Canada may be attributed to both corporate and government inaction. When pharmaceutical companies do not introduce safe and effective reproductive health medicines of significant public health benefit into the market for financial and political reasons, the right to health guaranteed by the ICESCR requires government action. By failing to facilitate the approval of mifepristone, given its potential to improve health care necessary to the realization of women's highest attainable standard of health, Canada may be failing to fulfill its international human rights obligations. j
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